来迪派韦/索磷布韦8周方案治疗HIV感染男性急性丙型肝炎
这是一项开放标签、2队列、1期临床试验的第二队列最终分析,评估来迪派韦/索磷布韦8周方案治疗合并慢性HIV-1感染的男性急性HCV感染的安全性和有效性。计划入组27人,以研究预设的历史peg-干扰素/利巴韦林持续病毒学应答60%为非劣效基准。结果显示全部27名参与者(100%)达到主要结局,即停药后12周持续病毒学应答(90%CI 90-100%),达到对60%历史基准的非劣效性,无治疗中断。
要点
- 来迪派韦/索磷布韦8周方案在合并HIV感染的男性急性HCV中报告100% SVR12。
- 该方案达到对60%历史SVR基准的非劣效性,且无治疗中断。
- 结果支持在HIV感染者中开展更短疗程直接抗病毒药物的更大规模研究。
核心结论
- 该多中心临床试验评估来迪派韦/索磷布韦8周方案治疗合并HIV感染的男性急性HCV感染,报告100%的SVR。
- 研究结果为在HIV感染者(包括基线HCV RNA高载量者)中开展更短疗程直接抗病毒治疗的更大规模研究提供了依据。
研究设计与样本
- 这是一项开放标签、2队列、1期临床试验(Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals)的第二队列最终分析。
- 第二队列评估来迪派韦/索磷布韦8周方案治疗合并慢性HIV-1感染者的急性HCV感染的安全性和有效性。
- 基于非劣效性标准并与研究定义的历史peg-干扰素/利巴韦林SVR 60%比较,第二队列计划入组27名参与者。
主要发现
- 共入组27名男性(9名西班牙裔;11名白人非西班牙裔;5名黑人非西班牙裔;2名亚裔或太平洋岛民;中位年龄46岁)。
- 大多数(96%)为HCV基因1型感染,59%具有有利的IL28B CC基因型;基线HCV RNA载量中位数为6.17 log10 IU/mL(四分位距4.51-6.55)。
- 全部参与者(100%)达到主要结局,即末次研究治疗给药后12周持续病毒学应答(SVR12)(90%CI 90-100%),达到对60%历史基准的非劣效性。
- 未发生治疗中断。
关键数值与推荐
- 主要结局为末次研究治疗给药后12周持续病毒学应答(SVR12),全部27名参与者(100%)达到(90%CI 90-100%)。
- 非劣效性比较基准为研究定义的历史peg-干扰素/利巴韦林SVR 60%,本队列达到非劣效性。
临床怎么用
- 对于合并HIV感染的男性急性HCV感染,可考虑来迪派韦/索磷布韦8周方案,但需注意该研究为1期小样本试验。
- 该结果提示在HIV感染者中可探索缩短疗程的直接抗病毒治疗,包括基线HCV RNA高载量者,但需更大规模研究验证。
局限性
- 该分析为1期、开放标签、小样本(27人)试验的第二队列最终分析,非劣效性比较基于研究定义的历史基准而非同期对照。
- 研究仅纳入男性、以HCV基因1型为主,结果外推至女性、其他基因型及更广泛人群需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Current guidelines for the management of hepatitis C virus (HCV) infections provide varying recommendations for the optimal treatment of acute HCV infections. There are limited data from small cohort studies to provide guidance on the best approach to treatment of this important patient population. METHODS: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals is an open-label, 2-cohort, Phase 1 clinical trial in which the second cohort assessed the safety and efficacy of 8 weeks of ledipasvir/sofosbuvir for the treatment of acute HCV infections in participants with chronic human immunodeficiency virus (HIV)-1 infections. This final analysis of the second cohort had a planned accrual of 27 participants, based on non-inferiority criteria, compared to the study-defined, historical, sustained virologic response (SVR) of 60% with pegylated-interferon/ribavirin. RESULTS: We enrolled 27 men (9 Hispanic; 11 White, non-Hispanic; 5 Black, non-Hispanic; 2 Asian or Pacific Islander; median age 46 years). Most (96%) had HCV genotype-1 infection and 59% had the favorable interleukin 28B CC genotype. The median baseline HCV RNA load was 6.17 log10 IU/mL (interquartile range 4.51 - 6.55). All participants (100%) achieved the primary outcome of a sustained virologic response 12 weeks after the date of the last dose of study treatment (90% confidence interval 90-100%), achieving non-inferiority versus the 60% historic benchmark. No treatment discontinuations occurred. CONCLUSIONS: This multicenter clinical trial, investigating 8 weeks of ledipasvir/sofosbuvir for acute HCV infections in men with HIV infections, reports a 100% SVR. This study provides the rationale for larger studies of shortened courses of direct-acting antiviral therapies in persons with HIV infections, including those with high baseline HCV RNA loads. CLINICAL TRIALS REGISTRATION: NCT02128217.
引用
- Naggie S, Fierer DS, Hughes MD, et al. Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals. Clin Infect Dis. 2019. PMID: 31220220. doi:10.1093/cid/ciy913
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。